Construction of a prognostic model based on CD8+T cell exhaustion-related gene set and investigation of the tumor immune microenvironment
10.3872/j.issn.1007-385x.2025.09.008
- VernacularTitle:基于CD8+T细胞耗竭基因集的预后模型构建及肿瘤免疫微环境研究
- Author:
Mengrou LI
1
;
Dongsheng CHEN
;
Hebin LIU
Author Information
1. 苏州大学 生物医学研究院,江苏 苏州 215123;中国医学科学院苏州系统医学研究所暨北京协和医学院 重大疾病共性机制研究全国重点实验室,江苏 苏州 215123
- Publication Type:Journal Article
- Keywords:
cancer;
exhausted T cell(Tex);
prognostic model;
biomarker
- From:
Chinese Journal of Cancer Biotherapy
2025;32(9):948-956
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To construct a prognostic model across multiple cancer types based on exhausted T cell(Tex)gene sets and to identify novel Tex cell markers.Methods:A pan-cancer single-cell dataset of CD8+T cells was utilized to identify the pan-cancer Tex gene set.Differential expression analysis and Cox regression analysis of TCGA data were performed to screen pan-cancer prognostic genes.These genes were then intersected with the Tex gene set,yielding a pan-cancer Tex prognostic gene set.Cox regression analysis was used to construct a pan-cancer prognostic model,and the model's performance was evaluated using Kaplan-Meier survival curve and receiver operating characteristic(ROC)curve analyses.In addition,correlation analysis was further applied to explore the role of TNFRSF18 in immunotherapy.Results:Cox regression analysis identified CXCL13,CDKN2A,TNFRSF18,and IL2RA as key prognostic genes,on which the prognostic model was constructed.Survival analysis showed that patients in the low-risk group exhibited significantly higher survival rates across various cancer types(P<0.05).Single-cell data analysis demonstrated that TNFRSF18 was specifically expressed in Tex cells and was significantly upregulated in tumor samples from various cancers(P<0.05).Conclusion:The pan-cancer Tex cell-based prognostic model showed robust predictive performance across various cancers.TNFRSF18 may function as a novel potential biomarker of Tex cells and play a role in cancer immunotherapy.
